TORONTO, July 15, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that data from the Phase 2 clinical trial of ELND005 in mild to moderate Alzheimer's disease patients will be presented at the International Conference on Alzheimer's Disease (ICAD) meeting, to be held July 16-21, 2011 in Paris, France. There will be two posters and one oral presentation covering safety, efficacy, imaging, biomarker and pharmacokinetic data from the Phase 2 clinical trial.
